Literature DB >> 23879434

Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature.

Kirsten E Pijls1, Daisy M A E Jonkers, Elhaseen E Elamin, Ad A M Masclee, Ger H Koek.   

Abstract

Recent evidence suggests that translocation of bacteria and bacterial products, such as endotoxin from the intestinal lumen into the systemic circulation is a contributing factor in the pathogenesis of chronic liver diseases and the development of complications in cirrhosis. In addition to alterations in the intestinal microbiota and immune system, dysfunction of the intestinal epithelial barrier may be an important factor facilitating bacterial translocation. This review aims to provide an overview of the current evidence of intestinal epithelial barrier dysfunction in human chronic liver diseases and cirrhosis, and to discuss possible contributing factors and mechanisms. Data suggest the presence of intestinal epithelial barrier dysfunction in patients with chronic liver diseases, but are more convincing in patients with cirrhosis, especially in those with complications. The barrier dysfunction can result from both direct and indirect effects of aetiological factors, such as alcohol and obesity, which can cause chronic liver diseases and ultimately cirrhosis. On the other hand characteristics of cirrhosis itself, including portal hypertension, alterations in the intestinal microbiota, inflammation and oxidative stress can affect barrier function of both small and large intestine and may contribute to the development of complications. In conclusion, there are indications for intestinal epithelial barrier dysfunction in patients with chronic liver diseases and especially in patients with cirrhosis, which can be caused by various factors affecting both the small and large intestine.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Bacterial translocation; cirrhosis; endotoxins; epithelial barrier; intestine; liver; microbiota; permeability; tight junctions

Mesh:

Year:  2013        PMID: 23879434     DOI: 10.1111/liv.12271

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  46 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

2.  Reactive Oxygen Species/Hypoxia-Inducible Factor-1α/Platelet-Derived Growth Factor-BB Autocrine Loop Contributes to Cocaine-Mediated Alveolar Epithelial Barrier Damage.

Authors:  Lu Yang; Xufeng Chen; Samantha M Simet; Guoku Hu; Yu Cai; Fang Niu; Yeonhee Kook; Shilpa J Buch
Journal:  Am J Respir Cell Mol Biol       Date:  2016-11       Impact factor: 6.914

3.  Quantitative Measure of Intestinal Permeability Using Blue Food Coloring.

Authors:  Stephanie A K Angarita; Sergio Duarte; Tara A Russell; Piotr Ruchala; Irmina A Elliott; Julian P Whitelegge; Ali Zarrinpar
Journal:  J Surg Res       Date:  2018-07-27       Impact factor: 2.192

Review 4.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver.

Authors:  Philipp Lutz; Hans Dieter Nischalke; Christian P Strassburg; Ulrich Spengler
Journal:  World J Hepatol       Date:  2015-03-27

Review 6.  The prenatal gut microbiome: are we colonized with bacteria in utero?

Authors:  R W Walker; J C Clemente; I Peter; R J F Loos
Journal:  Pediatr Obes       Date:  2017-04-26       Impact factor: 4.000

Review 7.  The significance of YKL-40 protein in liver fibrosis.

Authors:  Hui Tao; Jing-Jing Yang; Kai-Hu Shi; Cheng Huang; Lei Zhang; Xiong-Wen Lv; Jun Li
Journal:  Inflamm Res       Date:  2014-01-19       Impact factor: 4.575

8.  Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study.

Authors:  Matteo Bassetti; Maddalena Peghin; Alessia Carnelutti; Elda Righi; Maria Merelli; Filippo Ansaldi; Cecilia Trucchi; Cristiano Alicino; Assunta Sartor; Pierluigi Toniutto; Joost Wauters; Wim Laleman; Carlo Tascini; Francesco Menichetti; Roberto Luzzati; Pierluigi Brugnaro; Alessio Mesini; Stefania Raviolo; Francesco G De Rosa; Leonel Lagunes; Jordi Rello; George Dimopoulos; Arnaldo L Colombo; Marcio Nucci; Antonio Vena; Emilio Bouza; Patricia Muñoz; Mario Tumbarello; Raffaella Losito; Ignacio Martin-Loeches; Claudio Viscoli
Journal:  Intensive Care Med       Date:  2017-03-07       Impact factor: 17.440

Review 9.  The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma.

Authors:  Marco Sanduzzi Zamparelli; Alba Rocco; Debora Compare; Gerardo Nardone
Journal:  United European Gastroenterol J       Date:  2017-05-08       Impact factor: 4.623

Review 10.  New therapeutic agents for acromegaly.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2015-11-27       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.